Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of FGF23 on the Induction of Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease

NCT05356325 is registered in ClinicalTrials.gov with Maimónides Biomedical Research Institute of Córdoba as lead sponsor.

NCT NCT05356325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05356325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of FGF23 on the Induction of Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Phase
Observational
Overall status
Recruiting
Start date
October 18, 2021
Completion date
July 1, 2025
Enrollment
401 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, ckd, fibroblast growth factor 23